Possible involvement of PPAR-gamma receptor and nitric oxide pathway in the anticonvulsant effect of acute pioglitazone on pentylenetetrazole-induced seizures in mice

Epilepsy Research

Volumn 101, Issue 1-2, 2012, Pages 28-35

  Adabi Mohazab, Razieh ^a,b   Javadi Paydar, Mehrak ^a,b   Delfan, Bahram ^a,c   Dehpour, Ahmad Reza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c LORESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Mice; Nitric oxide; Pentylenetetrazole; Pioglitazone; Seizure threshold

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; AMINOGUANIDINE; ARGININE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PENTETRAZOLE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CLONIC SEIZURE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEIZURE THRESHOLD; SINGLE DRUG DOSE;

ANILIDES; ANIMALS; ANTICONVULSANTS; ARGININE; CONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GUANIDINES; MALE; MICE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PENTYLENETETRAZOLE; PPAR GAMMA; SEIZURES; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES;

EID: 84865073534     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2012.02.015     Document Type: Article

References (68)

1. Abdallah.D.M. Anticonvulsant potential of the peroxisomeproliferator-activated receptor gamma agonist pioglitazonein pentylenetetrazole-induced acute seizures and kindling in mice. Brain Res. 2010, 1351:246-253.
2. Aleshin S., Grabeklis S., Hanck T., Sergeeva M., Reiser G. Peroxisome Proliferator-Activated Receptor (PPAR)-γ Positively Controls and PPARα Negatively Controls Cyclooxygenase-2 Expression in Rat Brain Astrocytes through a Convergence on PPARβ/δ via Mutual Control of PPAR Expression Levels. Mol. Pharmacol. 2009, 76:414-424.
3. Allami N., Javadi-Paydar M., Rayatnia F., Sehhat K., Rahimian R., Norouzi A., Dehpour A.R. Suppression of nitric oxide synthesis by l-NAME reverses the beneficial effects of pioglitazone on scopolamine-induced memory impairment in mice. Eur. J. Pharmacol. 2011, 650:240-248.
4. Anjaneyulu M., Ramarao P. Protective effect of pioglitazone against multiple low-dose streptozotocin-induced diabetes in rats. Methods Find. Exp. Clin. Pharmacol. 2003, 25:205-208.
5. Bensinger S.J., Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008, 454:470-477.
6. Barbeito L.H., Pehar M., Cassina P., Vargas M.R., Peluffo H., Viera L., Estevez A.G., Beckman J.S. A role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis. Brain Res. Rev. 2004, 47:263-274.
7. Bell-Parikh L.C., Ide T., Lawson J.A., McNamara P., Reilly M., Fitzgerald G.A. Biosynthesis of 15-deoxydelta 12, 14-PGJ2 and the ligation of PPARgamma. J. Clin. Invest. 2003, 112:945-955.
8. Berger J.P., Akiyama T.E., Meinke P.T. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol. Sci. 2005, 26:244-251.
9. Berger J., Moller D.E. The mechanisms of action of PPARs. Annu. Rev. Med. 2002, 53:409-435.
10. Bernardo A., Levi G., Minghetti L. Role of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-Δ12, 14-prostaglandin J2 in the regulation of microglial functions. Eur. J. Neurosci. 2000, 12:2215-2223.
11. Bikjdaouene L., Escames G., Leon J., Ferrer J.M., Khaldy H., Vives F., Acuna-Castroviejo D. Changes in brain amino acids and nitric oxide after melatonin administration in rats with pentylenetetrazole-induced seizures. J. Pineal Res. 2003, 35:54-60.
12. Braissant O., Foufelle F., Scotto C., Dauca M., Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996, 137:354-366.
13. Breidert T., Callebert J., Heneka M.T., Landreth G., Launay J.M., Hirsch E.C. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 2002, 82:615-624.
14. Bolaños J.P., Almeida A., Stewart V., Peuchen S., Land J.M., Clark J.B., Heales S.J. Nitric oxide-mediated mitochondrial damage in the brain: mechanisms and implications for neurodegenerative diseases. J. Neurochem. 1997, 68:2227-2240.
15. Byun J.S., Lee S.H., Jeon S.H., Kwon Y.S., Lee H.J., Kim S.S., Kim Y.M., Kim M.J., Chun W. Kainic acid-induced neuronal death is attenuated by aminoguanidine but aggravated by l-NAME in mouse hippocampus. Korean J. Physiol. Pharmacol. 2009, 13:265-271.
16. Cho D.H., Choi Y.J., Jo S.A., Jo I. Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPARgamma-independent signaling pathways. J. Biol. Chem. 2004, 279:2499-2506.
17. Chu K., Lee S.T., Koo J.S., Jung K.H., Kim E.H., Sinn D.I., Kim J.M., Ko S.Y., Kim S.J., Song E.C., Kim M., Roh J.K. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia. Brain Res. 2006, 1093:208-218.
18. Chuang Y.C., Chen S.D., Lin T.K., Liou C.W., Chang W.N., Chan S.H., Chang A.Y. Upregulation of nitric oxide synthase II contributes to apoptotic cell death in the hippocampal CA3 subfield via a cytochrome c/caspase-3 signaling cascade following induction of experimental temporal lobe status epilepticus in the rat. Neuropharmacology 2007, 52:1263-1273.
19. Collino M., Aragno M., Mastrocola R., Gallichio M., Rosa A.C., Dianzani C., Danni O., Thiemermann C., Fantozzi R. Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur. J. Pharamacol. 2006, 530:70-80.
20. Cunard R., Ricote M., DiCampli D., Archer D.C., Kahn D.A., Glass C.K., Kelly C.J. Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J. Immunol. 2002, 168:2795-2802.
21. Dalkara T., Yoshida T., Irikura K., Moskowitz M.A. Dual role of nitric oxide in focal cerebral ischemia. Neuropharmacology 1994, 33:1447-1452.
22. De Luca G., Di Giorgio R.M., Macaione S., Calpona P.R., Di Paola E.D., Costa N., Cuzzocrea S., Citraro R., Russo E., De Sarro G. Amino acid levels in some brain areas of inducible nitric oxide synthase knock out mouse (iNOS-/-) before and after pentylenetetrazole kindling. Pharmacol. Biochem. Behav. 2006, 85:804-812.
23. Dehmer T., Heneka M.T., Sastre M., Dichgans J., Schulz J.B. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J. Neurochem. 2004, 88:494-501.
24. Diab A., Deng C., Smith J.D., Hussain R.Z., Phanavanh B., Lovett-Racke A.E., Drew P.D., Racke M.K. Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Δ(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 2002, 168:2508-2515.
25. Feil R., Kleppisch T. NO/cGMP-dependent modulation of synaptic transmission. Handb. Exp. Pharmacol. 2008, 184:529-560.
26. Feinstein D.L. Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease. Diabetes Technol. Ther. 2003, 5:67-73.
27. Feinstein D.L., Spagnolo A., Akar C., Weinberg G., Murphy P., Gavrilyuk V., Dello Russo C. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?. Biochem. Pharmacol. 2005, 70:177-188.
28. Garthwaite J. Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci. 1991, 14:60-67.
29. Gholipour T., Jabbarzadeh A., Riazi K., Rasouli A., Nezami B.G., Sharifzadeh M., Dehpour A.R. Role of nitric oxide in the anticonvulsive effect of progesterone. Epilepsy Behav. 2008, 13:579-584.
30. Heneka M.T., Feinstein D.L., Galea E., Gleichmann M., Wullner U., Klockgether T. Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. J. Neuroimmunol. 1999, 100:156-168.
31. Heneka M., Klockgether T., Feinstein D.L. Peroxisome proliferators-activated receptor-γ ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J. Neurosci. 2000, 20:6862-6867.
32. Hoffman M. A new role for gases: neurotransmission. Science 1991, 252:1788.
33. Homayoun H., Khavandgar S., Namiranian K., Gaskari S.A., Dehpour A.R. The role of nitric oxide in anticonvulsant and proconvulsant effects of morphine in mice. Epilepsy Res. 2002, 48:33-41.
34. Honar H., Riazi K., Homayoun H., Demehri S., Dehghani M., Vafaie K., Ebrahimkhani M.R., Rashidi N., Gaskari S.A., Dehpour A.R. Lithium inhibits the modulatory effects of morphine on susceptibility to pentylenetetrazole-induced clonic seizure in mice: involvement of a nitric oxide pathway. Brain Res. 2004, 1029:48-55.
35. Itoh K., Watanabe M., Yoshikawa K., Kanaho Y., Berliner L.J., Fujii H. Magnetic resonance and biochemical studies during pentylenetetrazole-kindling development: the relationship between nitric oxide, neuronal nitric oxide synthase and seizures. Neuroscience 2004, 129:757-766.
36. Jiang C., Ting A.T., Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-86.
37. Lesani A., Javadi-Paydar M., Khodadad T.K., Asghari-Roodsari A., Shirkhodaei M., Norouzi A., Dehpour A.R. Involvement of the nitric oxide pathway in the anticonvulsant effect of tramadol on pentylenetetrazole-induced seizures in mice. Epilepsy Behav. 2010, 19:290-295.
38. Liu J., Wang A., Li L., Huang Y., Xue P., Hao A. Oxidative stress mediates hippocampal neuron death in rats after lithium-pilocarpine-induced status epilepticus. Seizure 2010, 19:165-172.
39. Kamida T., Takeda Y., Fujiki M., Abe T., Abe E., Kobayashi H. Nitric oxide synthase and NMDA receptor expressions in cavernoma tissues with epileptogenesis. Acta Neurol. Scand. 2007, 116:368-373.
40. Kiaei M., Kipiani K., Chen J., Calingasan N.Y., Beal M.F. Peroxisome proliferator-activated receptor-gamma agonistextends survival in transgenic mouse model of amyotrophiclateral sclerosis. Exp. Neurol. 2005, 191:331-336.
41. Landreth G.E., Heneka M.T. Anti-inflammatory actions of persoxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. Neurobiol. Aging 2001, 22:937-944.
42. Leist M., Nicotera P. Apoptosis, excitotoxicity, and neuropathology. Exp. Cell Res. 1998, 239:183-201.
43. Lipton S.A., Choi Y.B., Sucher N.J., Chen H.S. Neuroprotective versus neurodestructive effects of NO-related species. Biofactors 1998, 8:33-40.
44. Luo Y., Yin W., Signore A.P., Zhang F., Hong Z., Wang S., Graham S.H., Chen J. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J. Neurochem. 2006, 97:435-448.
45. Mark R.E., Landreth G.E. PPARγ, neuroinflammation and disease. J. Neuroinflammation 2004, 1:5.
46. Matsumoto T., Noguchi E., Kobayashi T., Kamata K. Mechanisms underlying the chronic pioglitazone treatment-induced improvement in the impaired endothelium-dependent relaxation seen in aortas from diabetic rats. Free Radic. Biol. Med. 2007, 42:993-1007.
47. Michalik L., Auwerx J., Berger J.P., Chatterjee V.K., Glass C.K., Gonzalez F.J., Grimaldi P.A., Kadowaki T., Lazar M.A., O'Rahilly S., Palmer C.N., Plutzky J., Reddy J.K., Spiegelman B.M., Staels B., Wahli W. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev. 2006, 58:726-741.
48. Michalik L., Wahli W. PPARs mediate lipid signaling in inflammation and cancer. PPAR Res. 2008, 134059.
49. Miles P.D., Romeo O.M., Higo K., Cohen A., Rafaat K., Olefsky J.M. TNF-alpha induced insulin resistance in vivo and its prevention by troglitazone. Diabetes 1997, 46:1678-1683.
50. Moncada S., Palmer R.M.J., Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 1991, 43:109-123.
51. Moreno S., Farioli-Vecchioli S., Ceru M.P. Immunolocalization of peroxisome proliferator-activated receptors and retionoid X receptors in the adult rat CNS. Neuroscience 2004, 123:131-145.
52. Nidhi G., Balakishnan S., Pandhi P. Role of nitric oxide in electroshock and pentylenetetrazole seizure threshold in rats. Methods Find. Exp. Clin. Pharmacol. 1999, 21:609-612.
53. Okada K., Yamashita U., Tsuji S. Ameliorative effect of pioglitazone on seizure responses in genetically epilepsy-susceptible EL mice. Brain Res. 2006, 1102:175-178.
54. Okada K., Yuhi T., Tsuji S., Yamashita U. Cyclooxygenase-2 expression in the hippocampus of genetically epilepsy susceptible El mice was increased after seizure. Brain Res. 2001, 894:332-335.
55. Park E.Y., Cho J.J., Kim S.G. Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptorgamma and the retinoid X receptor heterodimer. Cancer Res. 2004, 64:3701-3713.
56. Ray A., Chakraborti A., Gulati K. Current trends in nitric oxide research. Cell. Mol. Biol. 2007, 53:3-14.
57. Riazi K., Roshanpour M., Rafiei-Tabatabaei N., Homayoun H., Ebrahimi F., Dehpour A.R. The proconvulsant effect of sildenafil in mice: role of nitric oxide-cGMP pathway. Br. J. Pharmacol. 2006, 147:935-943.
58. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptorgamma is a negative regulator of macrophage activation. Nature 1998, 391:79-82.
59. Roses A.D., Saunders A.M., Huang Y., Strum J., Weisgraber K.H., Mahley R.W. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). Pharmacogenomics J. 2007, 7:10-28.
60. Sadaghiani M.S., Javadi-Paydar M., Gharedaghi M.H., Fard Y.Y., Dehpour A.R. Antidepressant-like effect of pioglitazone in the forced swimming test in mice: the role of PPAR-gamma receptor and nitric oxide pathway. Behav. Brain Res. 2011, 224:336-343.
61. Schoonjans K., Staels K., Auwerx J. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochem. Biophys. Acta 1996, 1302:93-109.
62. Shimazu T., Inoue I., Araki N., Asano Y., Sawada M., Furuya D., Nagoya H., Greenberg J.H. A peroxisomeproliferator-activated receptor-gamma agonist reducesinfarct size in transient but not in permanent ischemia. Stroke 2005, 36:353-359.
63. Snyder S.H., Bredt D.S. Nitric oxide as a neural messenger. Trends Pharmacol. Sci. 1991, 12:125-128.
64. Starr M.S., Starr B.S. Paradoxical facilitation of pilocarpine-induced seizures in the mouse by MK-801 and the nitric oxide synthase inhibitor l-NAME. Pharmacol. Biochem. Behav. 1993, 45:321-325.
65. Steinman L., Martin R., Benard C., Conlon P., Oksenberg J.R. Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Ann. Rev. Neurosci. 2002, 25:491-505.
66. Theard M.A., Baughman V.L., Wang Q., Pelligrino D.A., Albrecht R.F. The role of nitric oxide in modulating brain activity and blood flow during seizure. Neuroreport 1995, 6:921-924.
67. Victor N.A., Wanderi E.W., Gamboa J., Zhao X., Aronowski J., Deininger K., Lust W.D., Landreth G.E., Sundararajan S. Altered PPARγ expression and activation after transient focal ischemia in rats. Eur. J. Neurosci. 2006, 24:1653-1663.
68. Yokoyama H., Mori N., Osonoe K., Kasai N., Hiramatsu M., Yoshimura T., Matsue T., Uchida I., Kobayashi N., Tsuchihashi N. Increase of central nitric oxide during pentylenetetrazol-induced seizures in rats. Psychiatry Clin. Neurosci. 1995, 49:S277-S279.